公开(公告)号：AU2013306098A1

公开(公告)日：2015-02-12

申请号：AU2013306098

申请日：2013-08-16

Applicant: WONG CHI-HUEY ,  FANG JIM-MIN ,  CHENG YIH SHYUN ,  ACADEMIA SINICA ,  TSAI CHARNG-SHENG

Inventor： WONG CHI-HUEY ,  FANG JIM-MIN ,  CHENG YIH-SHYUN E ,  TSAI CHARNG-SHENG

IPC: C07H7/00 ,  C12Q1/34

Abstract: Provided herein are novel irreversible sialidase inhibitors. These compounds can be conjugated with a detectable tagging moiety such as azide-annexed biotin via CuAAC for isolation and identification of sialidases. The provided compounds and the corresponding detectable conjugates are useful for detecting sialidase-containing pathogens and imaging

公开(公告)号：IL235117D0

公开(公告)日：2014-12-31

申请号：IL23511714

申请日：2014-10-19

Applicant: ACADEMIA SINICA

IPC: A61K20060101

Abstract: Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.

公开(公告)号：AU2009242530B2

公开(公告)日：2014-10-23

申请号：AU2009242530

申请日：2009-05-01

Applicant: ACADEMIA SINICA

Inventor： HO TUAN-HUA DAVID ,  HSING YUE-IE C ,  YU SU-MAY ,  LO SHUEN-FANG ,  KO SWEE-SUAK

IPC: A01H1/00 ,  A01H5/00 ,  C07K14/415 ,  C12N15/29 ,  C12N15/82

Abstract: A method of making a transgenic plant by transforming into a host plant a recombinant DNA construct that expresses in the transgenic plant a rice polypeptide and the transgenic plant thus produced.

公开(公告)号：ES2477549T3

公开(公告)日：2014-07-17

申请号：ES09798419

申请日：2009-06-16

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  WANG CHENG-CHI ,  YU ALICE L

IPC: G01N33/574 ,  G01N33/53

Abstract: Procedimiento diagnóstico de cáncer para los cánceres que son positivos para Globo H y positivos para Gb5, que comprende el suministro de una muestra que contiene anticuerpos de un sujeto del cual se sospecha que tiene cáncer, en donde dicha muestra es suero, saliva o líquido de ganglio linfático, la incubación de la muestra con Gb5 y uno o varios de Globo H, Bb2 y Bb3 para permitir que los anticuerpos de la muestra se fijen a Gb5 y a uno o varios de Globo H, Bb2 y Bb3, la medición de la cantidad de anticuerpos fijados a Gb5 y la cantidad de anticuerpos fijados a Globo H, a Bb2 o a Bb3, y la determinación de si el sujeto tiene el cáncer basándose en la cantidad de los anticuerpos fijados, en donde una proporción significativamente más alta de la cantidad de anticuerpos fijados a Globo H, Bb2 o Bb3 por la cantidad de anticuerpos fijados a Gb5, en comparación con la del sujeto sin cáncer, indica que el sujeto tiene un cáncer que es positivo para Globo H y positivo para Gb5.

公开(公告)号：CL2013001219A1

公开(公告)日：2014-04-04

申请号：CL2013001219

申请日：2013-05-03

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  TSENG YUNG-CHIEH ,  MA CHE

IPC: C12N1/00 ,  C12N7/00 ,  C12N15/09

公开(公告)号：CA2880701A1

公开(公告)日：2014-02-27

申请号：CA2880701

申请日：2013-08-16

Applicant: ACADEMIA SINICA ,  WONG CHI-HUEY ,  FANG JIM-MIN ,  CHENG YIH-SHYUN E ,  TSAI CHARNG-SHENG

Inventor： WONG CHI-HUEY ,  FANG JIM-MIN ,  CHENG YIH-SHYUN E ,  TSAI CHARNG-SHENG

IPC: C07H7/00 ,  C12Q1/34

Abstract: Provided herein are novel irreversible sialidase inhibitors. These compounds can be conjugated with a detectable tagging moiety such as azide-annexed biotin via CuAAC for isolation and identification of sialidases. The provided compounds and the corresponding detectable conjugates are useful for detecting sialidase-containing pathogens and imaging in situ sialidase activities under physiological conditions.

公开(公告)号：MY150648A

公开(公告)日：2014-02-14

申请号：MYPI20084331

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： YUAN-TSONG CHEN ,  SHUEN-LU HUNG ,  CHIH-LUNG SHEN ,  CHI-FENG CHANG ,  HSIN-YU LIN ,  WEI-HSUAN CHEN

IPC: C12Q1/68

Abstract: THIS INVENTION RELATES TO A METHOD OF DETERMINING THE PRESENCE OF CERTAIN HLA ALLELES, SUCH AS HLA-B* 1502 OR HLA-B*5801, AND A KIT FOR CARRYING OUT THIS METHOD. ALSO DISCLOSED IS A METHOD FOR ASSESSING WHETHER A PATIENT IS AT RISK FOR DEVELOPING ADVERSE DRUG REACTIONS (E.G., STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, OR HYPERSENSITIVITY SYNDROME) BASED ON THE PRESENCE OR ABSENCE OF A GENETIC MARKER (E.G., HLA-B* 1502, HLA-B*5801, OR HLA-B*46O1).

公开(公告)号：PL2016198T3

公开(公告)日：2013-12-31

申请号：PL07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

公开(公告)号：AU2013219191A1

公开(公告)日：2013-09-12

申请号：AU2013219191

申请日：2013-08-21

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHANG CHI-FENG ,  SHEN CHIH-LUNG ,  CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  CHEN WEI-HSUAN ,  LIN HSIN-YU

IPC: C12Q1/68

Abstract: The present invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for 5 developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：IL226143D0

公开(公告)日：2013-06-27

申请号：IL22614313

申请日：2013-05-02

Applicant: ACADEMIA SINICA ,  CHI HUEY WONG ,  CHE MA ,  YUNG CHIEH TSENG

IPC: C12P20060101

Abstract: Methods for producing virus particles and viral antigens with simplified glycosylation profiles, such as mono-glycosylated forms of HIV, HCV, Dengue virus, West Nile virus and influenza virus. When used as targets for vaccine production, the conserved nature of such sites generate vaccines that are less sensitive to viral mutations. Such methods may include the use of glycosylation inhibitors for production of viruses or viral antigens with simplified glycosylation profiles.